Sign in
TRVN Stock Price, Chart, Stats & News
Trevena, Inc.
Save
Trevena, Inc. (TRVN) does not currently pay a dividend.
–
Market cap
–
Current P/E
–
Forward P/E
TRVN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 46.56% |
Operating margin | -1129.22% |
Pretax margin | -1279.07% |
Net margin | -1289.25% |
Effective tax rate | -0.80% |
ROA | -99.22% |
ROE | -1014.58% |
D/E | -4.73x |
Interest coverage ratio | – |
TRVN valuation
P/E | – |
P/S | 0.01x |
P/B | -0.04x |
P/CF | -0.01x |
P/FCF | -0.00x |
P/OCF | -0.01x |
PEG | -0.00x |
EV multiple | 0.09x |
About
Trevena, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing innovative pharmaceutical solutions for individuals suffering from central nervous system disorders. Its pipeline features several promising drug candidates: OLINVYK (Oliceridine) injection: A G protein-biased mu-opioid receptor (MOR) ligand engineered to manage acute pain ranging from moderate to severe. TRV027: Aimed at addressing acute lung injury, which contributes to acute respiratory distress syndrome (ARDS) and abnormal blood clotting in patients with COVID-19.
Similar securities
Based on sector and market capitalization
Report issue